Teijin, Teijin Regenet, and Shinshu University Hospital, all based in Japan, entered into a joint research agreement regarding manufacturing technologies for cell and gene therapy products. The collaboration aims to advance manufacturing methods and strengthen Japan’s manufacturing infrastructure for cell and gene therapies with the goal of helping to contribute to the broader availability of these innovative treatments.
Cell and gene therapies, including CAR T-cell therapies, are expected to become increasingly important treatment options for cancer and other intractable diseases. In Japan, however, expanding the availability of specialized manufacturing personnel and manufacturing facilities remain significant challenges, underscoring the need for a more robust and sustainable supply framework.
Under the joint research agreement, Shinshu University Hospital’s expertise in CAR T-cell therapy R&D and clinical application will be combined with Teijin Regenet’s manufacturing and quality-management expertise cultivated through its CDMO business for regenerative medicine products. The partners said they will work together to enhance manufacturing technologies and strengthen the manufacturing base for cell and gene therapies.
The collaboration will also utilize the Cell Processing Center (CPC) at Shinshu University Hospital to explore future manufacturing automation and efficiency improvements. In addition, the partners will work to accumulate practical knowledge related to quality testing technologies and quality-control methodologies.
